Copyright 2008 by the Society for Neuro-Oncology
VEGF Trap induces antiglioma effect at different stages of disease
Departments of Neuro-Oncology (C.G.-M., J.F., J.X., C.A.C., J.F.G., W.K.A.Y.), Pathology (K.D.A.), and Biostatistics and Applied Mathematics (B.N.B.), The University of Texas M. D. Anderson Cancer Center, Houston, TX; Regeneron Pharmaceuticals, Inc., Tarrytown, NY (J.H.); USA
Address correspondence to C. Gomez-Manzano, Department of Neuro-Oncology, Unit 1002, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA (cmanzano{at}mdanderson.org).
 |
Abstract |
|---|
Pathological angiogenesis is a hallmark of cancer, specifically of glioblastomas, the most malignant and common primary brain tumor. Vascular endothelial growth factor (VEGF) is the key protein in the regulation of the hypervascular phenotype of primary malignant brain tumors. In this study, we tested VEGF Trap, a soluble decoy receptor for VEGF, in an intracranial glioma model. VEGF Trap was administered in short or prolonged schedules to animals bearing human gliomas at different stages of disease. Of importance, VEGF Trap treatment was efficacious in both initial and advanced phases of tumor development by significantly increasing overall survival. Furthermore, this effect was enhanced in animals treated with more prolonged regimens. In addition, we observed the emergence of a VEGF Trap-resistant phenotype characterized by tumor growth and increased invasiveness. Our results suggest that VEGF Trap will be effective in treating both patients with recurrent or progressive resectable glioblastoma and patients that have undergone extensive initial surgery. Finally, our results indicate that the clinical success of VEGF Trap may depend on a prolonged treatment in combined therapy aiming to simultaneously inhibit angiogenesis and tumor invasion.
Keywords: glioblastoma, therapy, VEGF, VEGF Trap
Received April 7, 2008; Accepted June 4, 2008
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Neuro Oncol:
- Moving Toward the Next Steps in Angiogenesis Therapy?
- W. K. Alfred Yung
Neuro Oncol 2008 10: 939.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  E. R. Gerstner, P.-J. Chen, P. Y. Wen, R. K. Jain, T. T. Batchelor, and G. Sorensen Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib Neuro Oncology, January 22, 2010; (2010): nop051v1 - nop051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Olson, J. Lu, H. Zhang, A. Shai, M. G. Chun, Y. Wang, S. K. Libutti, E. K. Nakakura, T. R. Golub, and D. Hanahan MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer Genes & Dev., September 15, 2009; 23(18): 2152 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. A. Yung Moving Toward the Next Steps in Angiogenesis Therapy? Neuro Oncology, December 1, 2008; 10(6): 939 - 939. [Full Text] [PDF]
|
|